eptinezumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5386 1644539-04-7

Description:

MoleculeDescription

Synonyms:

  • eptinezumab
  • eptinezumab-jjmr
  • vyepti
  • ALD403
Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 24, 2022 EMA H. LUNDBECK A/S
Feb. 21, 2020 FDA Lundbeck Seattle BioPharmaceuticals, Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Throat irritation 112.48 41.05 34 765 37613 63450610
Drug ineffective 67.62 41.05 73 726 1044692 62443531
Headache 60.64 41.05 55 744 633186 62855037
Therapeutic response shortened 49.81 41.05 14 785 11874 63476349

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 125.29 46.72 92 660 1080821 78662815
Throat irritation 110.42 46.72 32 720 40914 79702722
Headache 73.16 46.72 55 697 653717 79089919

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CD05 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Calcitonin gene-related peptide (CGRP) antagonists
FDA EPC N0000193952 Calcitonin Gene-related Peptide Antagonist
FDA MoA N0000193953 Calcitonin Gene-related Peptide Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Prevention of migraine attacks indication 408381007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Calcitonin gene-related peptide 1 GPCR BINDING AGENT Kd 10.82 DRUG LABEL DRUG LABEL
Calcitonin gene-related peptide 2 GPCR BINDING AGENT Kd 10.24 DRUG LABEL DRUG LABEL

External reference:

IDSource
8202AY8I7H UNII
C4694272 UMLSCUI
CHEMBL3833320 ChEMBL_ID
DB14040 DRUGBANK_ID
CHEMBL2109621 ChEMBL_ID
10308 INN_ID
D11303 KEGG_DRUG
10694 IUPHAR_LIGAND_ID
018285 NDDF
870524004 SNOMEDCT_US
871787004 SNOMEDCT_US
4039215 VANDF
4039216 VANDF
2282660 RXNORM
331473 MMSL
38196 MMSL
38197 MMSL
d09520 MMSL
C000628361 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vyepti HUMAN PRESCRIPTION DRUG LABEL 1 67386-130 INJECTION 100 mg INTRAVENOUS BLA 26 sections
Vyepti HUMAN PRESCRIPTION DRUG LABEL 1 67386-130 INJECTION 100 mg INTRAVENOUS BLA 26 sections
Vyepti HUMAN PRESCRIPTION DRUG LABEL 1 67386-130 INJECTION 100 mg INTRAVENOUS BLA 26 sections